← Leaderboards
H Trent Spencer
University Of South Carolina At Columbia
$5,129,255
Attributed
$11,336,609
Total exposure
16
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,336,609 · 16
By mechanism
R01$5,043,251 · 3
R43$1,776,691 · 6
R44$1,485,861 · 1
R42$1,126,694 · 1
R21$818,108 · 2
R56$385,276 · 1
Top collaborators
- Christopher Bradley Doering23 shared
- Gabriela Denning5 shared
- Wilbur A Lam4 shared
- Kelly C Goldsmith2 shared
- Brian G Petrich2 shared
- Lily Yang2 shared
- Lei Zhu2 shared
- Lovick Edward Cannon1 shared
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignGene TherapyBaseEngineeringCellsIn VivoGene TransferHemophilia APropertyBiomedical EngineeringHematopoietic Stem CellsIn VitroFactor ViiiAffectProductionRecombinantsSuccessClinical TrialsEffectivenessTransgenesGeneticHematopoieticPre-ClinicalCd34 Gene
Grant awards (35)
Allogeneic cell and gene therapy for neuroendocrine tumors$400,000
R43 · FY2025 · CA
ADEPT-STAR therapy for high risk neuroblastoma$400,000
R43 · FY2023 · CA
A microfluidics-based paradigm for clinical lentivector gene transfer$500,223
R01 · FY2021 · HL
A microfluidics-based paradigm for clinical lentivector gene transfer$500,223
R01 · FY2020 · HL
Tumor Stroma Breaking System for Efficient Delivery of Therapeutic Agents$224,860
R41 · FY2020 · CA
Tumor Stroma Breaking System for Efficient Delivery of Therapeutic Agents$105,503
R41 · FY2020 · CA
A microfluidics-based paradigm for clinical lentivector gene transfer$492,987
R01 · FY2019 · HL
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$376,888
R01 · FY2019 · HL
Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells$166,413
R21 · FY2019 · CA
A microfluidics-based paradigm for clinical lentivector gene transfer$492,987
R01 · FY2018 · HL
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$377,402
R01 · FY2018 · HL
Exploiting chemoimmunotherapy strategies with genetically-engineered gd T cells$200,637
R21 · FY2018 · CA
Ancestral Sequence Reconstruction Engineering of Coagulation Factors$391,891
R01 · FY2017 · HL
Preclinical Evaluation of Ancestral Coagulation Factor VIII$224,976
R43 · FY2017 · HL
Bioengineering Factor VIII through Ancestral Reconstruction$385,276
R56 · FY2016 · HL
Selection and preclinical validation of a lead candidate liver-directed AAV-FVIII expression cassette$224,223
R43 · FY2016 · HL
Bioengineered factor VIII gene therapy for hemophilia A$826,775
R44 · FY2015 · HL
Bioengineered factor VIII gene therapy for hemophilia A$659,086
R44 · FY2014 · HL
VLR-CART Cancer Immunotherapy$149,036
R43 · FY2014 · CA
Hematopoietic gene therapy for hemophilia A$368,900
R01 · FY2013 · HL
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2012 · HL
Bioengineered factor VIII gene therapy for hemophilia A$378,456
R43 · FY2012 · HL
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2011 · HL
Ex Vivo Gene Therapy for Hemophilia A$420,475
R42 · FY2010 · HL
Hematopoietic gene therapy for hemophilia A$387,500
R01 · FY2010 · HL
Ex Vivo Gene Therapy for Hemophilia A$706,219
R42 · FY2009 · HL
Hematopoietic gene therapy for hemophilia A$379,250
R01 · FY2009 · HL
Exploiting novel uses of gene-modified drug-resistant hematopoietic cells$231,092
R21 · FY2009 · HL · contact PI
Exploiting novel uses of gene-modified drug-resistant hematopoietic cells$13,175
R21 · FY2009 · HL · contact PI
Exploiting novel uses of gene-modified drug-resistant hematopoietic cells$206,791
R21 · FY2008 · HL · contact PI
ATTENUATION OF CHEMOTHERAPY INDUCED MYELOSUPPRESSION$106,400
R29 · FY2002 · CA
ATTENUATION OF CHEMOTHERAPY INDUCED MYELOSUPPRESSION$101,850
R29 · FY2001 · CA
ATTENUATION OF CHEMOTHERAPY INDUCED MYELOSUPPRESSION$30,514
R29 · FY2001 · CA
ATTENUATION OF CHEMOTHERAPY INDUCED MYELOSUPPRESSION$101,850
R29 · FY2000 · CA
ATTENUATION OF CHEMOTHERAPY INDUCED MYELOSUPPRESSION$29,751
R29 · FY2000 · CA